At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Kyushu University; Medical College of Georgia; Mitsubishi Tanabe Pharma Corporation; Vanderbilt University School of Medicine
- Class Antiasthmatics; Antihypertensives; Muscle relaxants
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Angina pectoris; Asthma; Cardiovascular disorders; Erectile dysfunction; Hypertension
Most Recent Events
- 17 Nov 2009 Discontinued - Preclinical for Angina pectoris in Japan (unspecified route)
- 17 Nov 2009 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 17 Nov 2009 Discontinued - Preclinical for Cardiovascular disorders in Japan (unspecified route)